No evidence of increased suicidal ideation risk linked with GLP-1 drug semaglutide
A large US study, reported in Nature Medicine, has found no evidence that taking drugs that include diabetes and weight-loss medication semaglutide is tied to an increase in suicidal thoughts.
The study analysed medical data from more than 1.8 million patients to uncover the effect semaglutide - the active ingredient in Danish diabetes care giant Novo Nordisk's (NOV: N) diabetes medication Ozempic - has on mental health. This also included in the study was another of Novo Nordisk's semaglutide-based medicines, Wegovy, which is specifically authorized for the treatment of obesity.
Following an investigation, the European Medicines Agency last November announced it couldn't conclusively say if there is a link between GLP-1s and thoughts of self-harm, but it is still studying the issue. The US Food and Drug Administration also said recently that it is investigating possible side effects reported to the agency, including suicidal thought.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze